Phase 2 Stroke Trial, Recruiting NCT03843463 Sponsor: Johns Hopkins University Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT03843463
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had an acute ischemic stroke (a stroke caused by a blocked blood vessel) on the left side of the brain
  • People who spoke English fluently before their stroke, by their own report
  • People who are able to give informed consent themselves, or who have a legally authorised representative who can do so on their behalf
  • People who are 18 years of age or older
  • People who are within 5 days of when their stroke began
  • People who were right-handed before their stroke, by their own report
  • People who have been diagnosed with aphasia (difficulty with language and communication after stroke), confirmed by a specific language assessment test called the Western Aphasia Battery-Revised

Who may not be able to join:

  • People who have a previous neurological condition affecting the brain, including a previous stroke that caused symptoms
  • People who have a diagnosis of schizophrenia, autism, or another psychiatric or neurological condition that affects naming or language
  • People who have additional risk factors for a specific heart rhythm problem called torsades de pointes — for example, heart failure, low potassium levels, or a family history of Long QT Syndrome
  • People who are currently experiencing severe depression, based on a score above 15 on a standard depression questionnaire (PHQ-9)
  • People who have uncorrected vision loss or hearing loss, by their own report
  • People who were taking any FDA-approved antidepressant medication at the time their stroke began
  • People who are currently taking certain medications, including MAOIs (a type of antidepressant), pimozide, drugs that affect heart rhythm (QT interval), triptans, or other medications that may not be safely combined with the study drug escitalopram (confirm with trial site)
  • People whose heart rhythm test (ECG) shows a QTc measurement greater than 450 milliseconds, or whose blood sodium level is below 130 at the start of the study
  • People who were pregnant at the time of their stroke, or who are planning to become pregnant during the study period

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Argye Hillis-Trupe, MD, Johns Hopkins University

Phone: (410) 614-2381

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
18 July 2021
Est. completion
18 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Philadelphia Naming Test short-form accuracy score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov